Lung Cancer

The FDA has approved bevacizumab-adcd, a bevacizumab biosimilar, for the treatment of six types of cancer.

Sunvozertinib provided beneficial antitumor activity when used as a second- or later-line treatment in patients with non­­­–small cell lung cancer harboring EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy.

Pembrolizumab plus platinum/pemetrexed continued to demonstrate an overall survival and progression-free survival benefit vs platinum/pemetrexed alone in patients with previously untreated, metastatic squamous non–small cell lung cancer.

Pembrolizumab plus chemotherapy demonstrated sustained improvements in progression-free survival and overall survival vs placebo plus chemotherapy in patients with treatment-naïve, metastatic squamous non–small cell lung cancer regardless of PD-L1 expression level.

In a 9 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the benefits of poziotinib do not outweigh its risks for the treatment of patients with HER2 exon 20 insertion–mutated non–small cell lung cancer.

The China National Medical Products Administration has approved the supplemental new drug application seeking the approval of toripalimab plus pemetrexed and platinum as a frontline treatment in unresectable, locally advanced or metastatic, nonsquamous non–small cell lung cancer not harboring EGFR mutations or ALK fusions.

Dr Solange Peters shares the molecular testing results for the patient in the presented clinical scenario.

Mark A. Socinski, MD, debates the merits of liquid versus tissue tumor biopsies in NSCLC biomarker testing.

Investigators are making progress in delineating the optimal use of radiation therapy for the treatment of patients with small cell lung cancer, which remains a cornerstone of therapy for the malignancy, particularly in limited-stage disease.

Andrew Ip, MD, discusses carboplatin, pemetrexed, and pembrolizumab as first-line therapy in recurrent/metastatic non–small cell lung cancer.

During the past 15 years, breakthrough discoveries have revolutionized the treatment landscape for most patients with lung cancer, progress that has helped fuel an overall drop in cancer mortality.

Timothy Craig Allen, MD, JD, FCAP, explains how he approaches biomarker testing in NSCLC and what testing he would have ordered in the presented scenario.

A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.

Dr Elamin discusses results from a phase 2 study of poziotinib efficacy in EGFR exon 20–mutant non–small cell lung cancer and highlights the agent’s sensitivity in relation to insertion location.

The clinical benefit and tolerable safety profile of trastuzumab deruxtecan was maintained at 5.4 kg/mg vs 6.4 kg/mg in patients with HER2-mutated non–small cell lung cancer, confirming the benefit-risk ratio of the FDA-approved dose.

Sotorasib doubled the rate of progression-free survival at 12 months and reduced the risk of progression or death by 34% compared with docetaxel for patients with previously treated non–small cell lung cancer with KRAS G12C mutations.

Atezolizumab led to an almost doubling in the rate of 2-year overall survival compared with vinorelbine or gemcitabine in patients with advanced platinum-ineligible non–small cell lung cancer.

Patients with completely resected non–small cell lung cancer did not derive a significant benefit with adjuvant canakinumab vs placebo.

Tislelizumab continued to demonstrate an improved clinical benefit compared with docetaxel in both Asian and non-Asian patients with previously treated advanced non–small cell lung cancer.

Adjuvant osimertinib resulted in a 77% reduction in the risk of disease recurrence or death in patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer, with a disease-free survival improvement observed irrespective of prior adjuvant chemotherapy or disease stage.

MEDI5752 plus chemotherapy doubled the duration of response and extended survival compared with pembrolizumab in patients with treatment-naïve nonsquamous non–small cell lung cancer.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

The frontline combination of tremelimumab plus durvalumab and chemotherapy generated a long-term overall survival benefit in patients with metastatic non–small cell lung cancer.

Increased exposure to particulate matter may be a mechanistic driver for EGFR-positive non–small cell lung cancer, prompting a focus on limiting exposure to air pollutants and an increased need for molecular testing.

Preoperative nivolumab with or without relatlimab increased surgical feasibility in patients with resectable non–small cell lung cancer.